Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.20.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
12 Months Ended
Jul. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Patent and licensing costs   $ 742,918 $ 842,325
Research and development costs   $ 820,906 $ 40,703
Concentration of risk, percentage   10.00% 10.00%
Deferred setup and organization costs, amortization period   180 months  
Unrecognized tax benefits  
Collaboration Agreement [Member]      
Research and development costs   87,471  
Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member]      
Collaboration agreement description Effective as of July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with GEIS to carry out a clinical trial entitled "Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma". The Company estimates that this clinical trial will be completed and results will be published by June 2023.    
Research and development costs   $ 87,471  
Concentration of risk, percentage   10.70%